Section Arrow
ABVX.NASDAQ
- Abivax SA
Quotes are at least 15-min delayed:2026/02/09 10:02 EST
Regular Hours
Last
 117.88
+0.21 (+0.18%)
Day High 
117.99 
Prev. Close
117.67 
1-M High
130.13 
Volume 
95.00K 
Bid
117.64
Ask
117.99
Day Low
116.71 
Open
117.58 
1-M Low
107.42 
Market Cap 
9.23B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 114.52 
20-SMA 117.04 
50-SMA 121.58 
52-W High 148.83 
52-W Low 4.77 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.44/-2.31
Enterprise Value
9.28B
Balance Sheet
Book Value Per Share
7.61
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
LIMNLiminatus Pharma Inc2.155+0.315+17.12%-- 
RAPTRAPT Therapeutics Inc57.72+0.03+0.05%-- 
RXRXRecursion Pharmaceuticals3.895-0.085-2.14%-- 
HUMAHumacyte1.075+0.1367+14.57%-- 
IBRXImmunityBio6.03-0.02-0.33%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.